$TTAM

TTAM Maintained by Citigroup -- Price Target Lowered to $18.00

Citigroup maintained a 'Buy' rating for Titan America (TTAM) but lowered its price target from $21.00 to $18.00. The company's P/E ratio is 13.94x, below its 5-year median, and its GF Score™ is 22/100, indicating financial weaknesses. Insider activity shows no recent changes. TTAM operates in the building materials sector with a market cap of $2.47 billion.

Original reporting
Published Oct 2, 2026, 6:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 7:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TTAM
Bearish
high confidence
Mentioned
$TTAM
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$TTAMBearishMed
01

Why it matters

Analyst target reduction may prompt short‑term selling, but the maintained 'Buy' rating could attract value‑seeking investors.

02

Market read

The price‑target cut is the primary new information, offering a modest trading signal for TTAM.

03

What to watch

Potential cost‑inflation pressures in raw material inputs and upcoming infrastructure spending could support the stock despite the lower target.

Relevance 7/10Novelty 7/10Timing: today

Background

Titan America operates in the building‑materials segment, producing cement, aggregates, and ready‑mix concrete for the eastern U.S.

Company-level read

Ticker impact

$TTAMBearishHigh confidence
Context

Citigroup lowered its price target for Titan America (TTAM) from $21.00 to $18.00, a 14.3% reduction.

Expected impact

likely downside as investors price in the lower target

Evidence & confidence

Analyst price‑target cuts historically trigger sell pressure, especially when the rating remains unchanged.

Market effects

Basic Materials sector may see modest repricing as peers' valuations are compared to TTAM's new target.

U.S. construction‑materials market could experience slight sentiment drag.

Limited; impact confined to TTAM and its immediate peers.

Counterpoint

The unchanged 'Buy' rating may indicate that the target cut is a temporary adjustment rather than a fundamental downgrade.

Key entities

  • Titan America

    U.S. building‑materials producer (ticker TTAM).

  • Citigroup

    Issued the price‑target downgrade.

Related articles

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.